The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect

When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect

March 22, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

To reduce costs or as an insurance company requirement, rheumatologists may switch patients from a biologic treatment to a biosimilar. Although double-blinded clinical trials have shown biosimilar treatments to be effective and comparable to their biologic reference product, studies have revealed higher discontinuation rates with biosimilars than with the reference biologic.

You Might Also Like
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
  • From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
Also By This Author
  • Patients with Non-Classic Carpal Tunnel Syndrome Can Benefit from Surgery

This discrepancy has led some to question whether patients are discontinuing biosimilar treatments because of unwarranted concerns. This nocebo effect may be the result of negative expectations for biosimilars, as well as mistrust of healthcare systems. Although the nocebo effect has important implications in rheumatology, few interventions exist to reduce it and those that do exist have not resulted in documented positive outcomes when compared with historical cohorts.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Juliette Petit, MD, a rheumatologist at the Hopital Saint-Antoine, Paris, and colleagues designed a nocebo intervention centered on tailored communication and led by nurses. They compared the effect of the intervention on retention rates with the retention rates of historical cohorts of patients taking biologic treatments, finding their intervention reduced the nocebo effect on non-medical medication switches from infliximab to the biosimilar infliximab-abda. The investigators published the results of their observational study online Jan. 25 in RMD Open.1

Patient Centered
The team began by investigating patients’ needs and perspectives. They used these findings as the basis of an intervention of structured communication focused on building a trustful relationship between patients and nurses and ensuring consistent communication from all healthcare professionals. Next, the researchers provided the intervention to 45 patients (17 with rheumatoid arthritis and 28 with spondyloarthritis) before they received a non-medical medication switch from infliximab to infliximab-abda. The investigators then monitored patients from the time of the switch in March 2018 through August 2019, comparing their findings with a historical cohort.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After 34 weeks, the infliximab-abda group had a retention rate of 91.2%, a rate similar to the historical cohort of patients taking the reference biologic and significantly higher than those seen in other European cohorts with similar follow-ups. At the 12-month follow-up, the retention rate for the biosimilar group was 84.5% compared with 88.4% for the historical cohort, which was similar to rates seen in three published studies of patients taking biologics. Additionally, the investigators found no difference in withdrawal-free survival in their two cohorts. Moreover, patient global scores, disease activity scores in 28 joints and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were the same at baseline and one-year follow-up.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics & Biosimilars, infliximab, infliximab-abda, non-medical switching, Renflexis (infliximab-abda)

You Might Also Like:
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
  • From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)